Paolo A. Ascierto

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" — Italy

Medicine · Health Sciences

126h-index107.5kcitations1.7kworks7.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(773), Melanoma and MAPK Pathways(591), CAR-T cell therapy research(495), Cutaneous Melanoma Detection and Management(383), Immunotherapy and Immune Responses(358)

Publications1.6k total

Immune-related disorders in patients with Thymic Epithelial Tumors: from pathogenesis to tailored interventions
Lung Cancer·2026
Reframing adjuvant immunotherapy in melanoma: all of it starts with priming
Journal for ImmunoTherapy of Cancer·2025Open Access
Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S9 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S10 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Methods S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S11 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
page 1 of 82Next →

Frequent Co-authors

Michele Maio(24), Dirk Schadendorf(20), Caroline Robert(17), Reinhard Dummer(14), James Larkin(13), Vanna Chiarion‐Sileni(13), Piotr Rutkowski(12), Georgina V. Long(12), Célèste Lebbé(12), Claus Garbe(10), Mario Mandalà(10), Jean‐Jacques Grob(9), Michael Smylie(9), Grant A. McArthur(9), Jedd D. Wolchok(9), Ralf Gutzmer(9), F. Stephen Hodi(8), Alexander M.M. Eggermont(8), René González(7), Matteo S. Carlino(7)